Document is current
Any future updates will be listed below
-
Authors
Tougeron, David https://orcid.org/0000-0002-8065-9635
Louvet, Christophe
Desramé, Jérôme
Evesque, Ludovic
Angelergues, Antoine https://orcid.org/0009-0005-4876-918X
Carnot, Aurélien https://orcid.org/0000-0003-2933-4066
Breysacher, Gilles
Zaanan, Aziz
Etchepare, Nicolas
Mabro, May
Kaluzinski, Laure
Petorin, Caroline
Chibaudel, Benoist
Aparicio, Thomas https://orcid.org/0000-0001-8834-6927
Bodere, Anaïs
Rinaldi, Yves
Le Malicot, Karine https://orcid.org/0000-0002-3226-8525
Emile, Jean-François https://orcid.org/0000-0002-6073-4466
Lepage, Côme
Baures, Aurélia
Djamai, Hanane
Taly, Valérie
Laurent-Puig, Pierre https://orcid.org/0000-0001-8475-5459
-
Funding
Funding for this research was provided by:
AstraZeneca (none)
FFCD: fédération francophone de cancérologie digestive
- License Information
-
More Information
Article History
Received: 22 July 2024
Accepted: 14 April 2025
First Online: 24 April 2025
Competing interests
: D.T. reports consultancy, advisory fees, honoraria from Servier, Pierre Fabre, Merck Serono, MSD, BMS, A.Z., Roche, Sanofi; research funding from Sandoz, AstraZenenca, Servier, MSD; travel grants from Pierre Fabre, MSD, Servier, Roche. P.L.P. reports consultancy, advisory fees, and honoraria from Servier, Pierre Fabre, and Biocartis. T.A. reports advisory fees, and honoraria from Pierre Fabre, Servier, MSD, BMS, Bayer. B.C. reports advisory fees from Bayer, MSD, BMS, Sanofi, and Roche, and honoraria from Amgen, Roche, Sanofi, Merck, BMS, SeqOne Genomics, and Pierre Fabre. A.Z. reported personal fees from Amgen, AbbVie, Astellas, Gilead, Merck, Sanofi, Roche, Servier, MSD, BMS, Pierre Fabre, Daiichi Sankyo, AstraZeneca, Zymeworks; grants from Amgen outside the submitted work. P.L.P. and V.T. are one of the founders of MethysDX. The other authors declare that there are no competing interests.
